Company Profile

Liminal BioSciences Inc. is a Canada-based is a development-stage biopharmaceutical company. The Company is focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using its drug discovery platform. The Company is developing Selective G-protein coupled receptor 84 (GPR84) Antagonist and Oxo-eicosanoid receptor 1 (OXER1) Antagonist. Its GPR84 is a pro-inflammatory target primarily expressed on cells associated with the immune system and its expression levels increase significantly during periods of inflammatory stress. Inhibition of GPR84 can inhibit neutrophil and macrophage migration and reduce cytokine release. GPR84 antagonist program is at the pre-clinical-stage. The OXER1 is a G protein-coupled receptor (GPCR) that is highly selective for 5-Oxo-eicosatetraenoic acid (5-oxo-ETE), a potent human eosinophil chemo-attractant. OXER1 antagonist program is in the pre-clinical-stage.

Employees

Sector

Biotechnology & Medical Research

More about the company

23-09-26	Liminal BioSciences Inc.(NasdaqCM:LMNL) dropped from NASDAQ Composite Index	CI
23-09-25	Structured Alpha LP, a fund managed by Thomvest Ventures, Inc. completed the acquisition of remaining 38.8% stake in Liminal BioSciences Inc. (DB:PJ2).	CI
23-09-15	Liminal BioSciences Inc. - Shareholder/Analyst Call
23-08-08	Liminal BioSciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-07-12	Top Midday Gainers	MT
23-07-12	Liminal BioSciences Agrees to Be Acquired by Structured Alpha for $8.50 per Share; Shares Soar Pre-Bell	MT
23-06-05	Liminal BioSciences Inc. - Shareholder/Analyst Call
23-06-02	Liminal BioSciences Provides R&D Update	CI
23-05-09	Liminal BioSciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
23-04-05	Sector Update: Healthcare Stocks Rising Late Afternoon	MT
23-04-05	Top Midday Gainers	MT
23-04-05	Liminal BioSciences Shares Soar on Structured Alpha Takeover Bid	MT
23-04-05	Toronto Stocks Retreat; WSP Global Shares Down, Plans to Buy Calibre Professionals	DJ

21-06-24	Liminal BioSciences : HC Wainwright Downgrades Liminal BioSciences to Neutral From Buy	MT
21-06-02	Liminal BioSciences : Piper Sandler Downgrades Liminal BioSciences to Neutral From Overweight, Adjusts Price Target to $4.50 From $22	MT
21-02-18	Liminal BioSciences : HC Wainwright Starts Liminal BioSciences at Buy with $11 Price Target	MT
20-12-21	Liminal BioSciences : Piper Sandler Starts Liminal BioSciences at Overweight With $22 Price Target	MT

23-09-26	Liminal BioSciences : Notice	PU
23-09-12	Liminal BioSciences : Supplement to the Arrangement Circular – Special Meeting September 2023	PU
23-08-17	Liminal BioSciences : Notice of Special Meeting of Shareholders and Management Information Circular dated August 16, 2023 - Form 6-K	PU
23-08-16	Liminal BioSciences : Form of Proxy – Special Meeting September 2023	PU
23-08-16	Liminal BioSciences : Other	PU

Manager	Title	Age	Since
Bruce Pritchard CEO	Chief Executive Officer	53	2020-11-12
Nicole Rusaw-George DFI	Director of Finance/CFO	53	2022-03-01
Marie Iskra LAW	General Counsel	50	2019-08-31

Director	Title	Age	Since
Alek Krstajic CHM	Chairman	62	2020-08-31
Eugene Siklos BRD	Director/Board Member	62	2020-08-31

Liminal BioSciences Inc. Stock

Stocks

PJ2

CA53272L2021

Biotechnology & Medical Research

Latest news: Liminal BioSciences Inc.

Analysts' recommendations: Liminal BioSciences Inc.

Press Releases: Liminal BioSciences Inc.

News in other languages: Liminal BioSciences Inc.

Managers and Directors: Liminal BioSciences Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/1/23	Thomvest Asset Management, Inc.	Tax	Company	17,888,516	-
10/1/23	Thomvest Asset Management, Inc.	Marche	Company	1,261,921	38.8339%
10/1/23	Thomvest Asset Management, Inc.	Tax	Company	17,888,516	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LIMINAL BIOSCIENCES INC.	-.--%	+6.09%	-	-	13.02M
LONZA GROUP AG	+0.56%	-5.82%	-2.45%	+9.99%	45.48B
REVOLUTION MEDICINES, INC.	+0.66%	-2.34%	+340.62%	+524.38%	43.68B
IQVIA HOLDINGS INC.	+1.49%	-0.78%	+41.90%	+22.65%	43.09B
BEONE MEDICINES AG	+2.11%	-1.24%	+9.09%	+76.85%	39.4B
CELLTRION, INC.	+0.34%	-4.94%	+9.34%	+40.23%	31.91B
ASCENDIS PHARMA A/S	+0.53%	-2.08%	-	-	17.31B
MEDPACE HOLDINGS, INC.	+1.34%	+0.70%	+21.35%	+111.39%	16.4B
EUROFINS SCIENTIFIC SE	+2.07%	-0.77%	+13.07%	+32.89%	14.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.85%	-5.33%	+78.63%	+34.13%	13.28B
Average	+0.72%	-2.97%	+63.95%	+106.56%	29.42B
Weighted average by Cap.	+0.94%	-3.26%	+76.00%	+126.85%